EXEL logo

Exelixis Inc

EXEL

EXEL: Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

more

Show EXEL Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of EXEL by members of U.S. Congress

Politician Type Traded
Donna Shalala House / D Sale $1,001 - $15,000 Jun. 04, 2019
Donna Shalala House / D Sale $1,001 - $15,000 Apr. 16, 2019
Donna Shalala House / D Purchase $1,001 - $15,000 Feb. 06, 2019
Donna Shalala House / D Purchase $1,001 - $15,000 Jan. 09, 2019
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by EXEL's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $460,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $440,000 Apr 25, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $330,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $320,000 Oct 19, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $300,000 Jul 19, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $290,000 Apr 19, 2022 Issue: Health Issues
  • $280,000 Jan 19, 2022 Issue: HEALTH ISSUES
  • $230,000 Oct 20, 2021 Issue: HEALTH ISSUES
  • $220,000 Jul 20, 2021 Issue: HEALTH ISSUES
  • $220,000 Apr 19, 2021 Issue: HEALTH ISSUES
  • $220,000 Jan 20, 2021 Issue: HEALTH ISSUES
  • $240,000 Oct 20, 2020 Issue: HEALTH ISSUES
  • $240,000 Jul 20, 2020 Issue: HEALTH ISSUES
  • $220,000 Apr 20, 2020 Issue: HEALTH ISSUES
  • $190,000 Jan 21, 2020 Issue: HEALTH ISSUES
  • $180,000 Oct 21, 2019 Issue: Health Issues
  • $320,000 Jul 22, 2019 Issue: Health Issues
  • $300,000 Apr 22, 2019 Issue: Health Issues
  • $20,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $60,000 Jan 17, 2019 Issue: Health Issues
  • $60,000 Oct 09, 2018 Issue: Health Issues
  • $60,000 Jul 18, 2018 Issue: Health Issues
  • $50,000 Apr 19, 2018 Issue: Health Issues
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of EXEL in WallStreetBets Daily Discussion

EXEL News

Recent insights relating to EXEL

CNBC Recommendations

Recent picks made for EXEL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in EXEL

Corporate Flights

Flights by private jets registered to EXEL